Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain
Name:
Cierpicki_PRC1_NCB2021 (2).pdf
Size:
13.11Mb
Format:
PDF
Description:
Accepted Article
Type
ArticleAuthors
Shukla, ShirishYing, Weijiang
Gray, Felicia
Yao, Yiwu
Simes, Miranda L.

Zhao, Qingjie
Miao, Hongzhi
Cho, Hyo Je
González-Alonso, Paula

Winkler, Alyssa
Lund, George
Purohit, Trupta
Kim, EunGi
Zhang, Xiaotian
Ray, Joshua M.
He, Shihan
Nikolaidis, Caroline
Ndoj, Juliano
Wang, Jingya
Jaremko, Lukasz

Jaremko, Mariusz

Ryan, Russell J. H.

Guzman, Monica L.

Grembecka, Jolanta

Cierpicki, Tomasz

KAUST Department
Biological and Environmental Science and Engineering (BESE) DivisionBioscience Program
Date
2021-06-21Online Publication Date
2021-06-21Print Publication Date
2021-07Embargo End Date
2021-12-21Submitted Date
2020-04-21Permanent link to this record
http://hdl.handle.net/10754/669743
Metadata
Show full item recordAbstract
Polycomb repressive complex 1 (PRC1) is an essential chromatin-modifying complex that monoubiquitinates histone H2A and is involved in maintaining the repressed chromatin state. Emerging evidence suggests PRC1 activity in various cancers, rationalizing the need for small-molecule inhibitors with well-defined mechanisms of action. Here, we describe the development of compounds that directly bind to RING1B–BMI1, the heterodimeric complex constituting the E3 ligase activity of PRC1. These compounds block the association of RING1B–BMI1 with chromatin and inhibit H2A ubiquitination. Structural studies demonstrate that these inhibitors bind to RING1B by inducing the formation of a hydrophobic pocket in the RING domain. Our PRC1 inhibitor, RB-3, decreases the global level of H2A ubiquitination and induces differentiation in leukemia cell lines and primary acute myeloid leukemia (AML) samples. In summary, we demonstrate that targeting the PRC1 RING domain with small molecules is feasible, and RB-3 represents a valuable chemical tool to study PRC1 biology.Citation
Shukla, S., Ying, W., Gray, F., Yao, Y., Simes, M. L., Zhao, Q., … Cierpicki, T. (2021). Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain. Nature Chemical Biology. doi:10.1038/s41589-021-00815-5Sponsors
This work was funded by the National Institute of Health (NIH) R01 grants CA207272, CA226759 and CA240514 to T.C., CA201204, CA244254 and CA160467 to J.G. and LLS Scholar grants (1340-17) to T.C. and (1215-14) to J.G. This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract number DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor (grant 085P1000817). TEX and MLL–ENL cells were received from J. Dick, University Health Network, Toronto, Canada. We thank M. Carroll and G. Danet-Desnoyers from the Stem Cell and Xenograft Core at the University of Pennsylvania for providing a human AML primary sample.Publisher
Springer Science and Business Media LLCJournal
Nature Chemical Biologyae974a485f413a2113503eed53cd6c53
10.1038/s41589-021-00815-5